Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Acorda Reports Negative Top Line Results of Study Exploring Ampyra 5mg Efficacy
Aug. 15, 2012
Acorda Therapeutics has reported negative top line results from post-marketing commitment study exploring 5mg dose of Dalfampridine-ER in multiple sclerosis (MS) patients.
Pharmaceutical Business Review
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing